ABL1 and cancer: Imatinib has been approved by the FDA since 2001 and can be used to treat several types of RTKs-associated cancers, including ABL (Tyrosine-protein kinase ABL1), BCR-ABL (fusion gene of breakpoint cluster region and Tyrosine-protein kinase ABL1 genes), PDGFRA (platelet-derived growth factor receptor A), and c-Kit tyrosine kinases.